3Q26 NP Jumped YoY; Profitability Notably Improved
发布时间:2026-11-09 来源:华泰证券
YHLO Biotech reported 9M26 revenue of RMB1,429mn (+11.04% YoY), attributable NP of RMB144mn (+137.58% YoY), and recurring NP of RMB152mn (+50.66% YoY). In 3Q26, revenue was RMB541mn (+13.07% YoY), attributable NP was RMB73mn (+114.97% YoY), and recurring NP was RMB79mn (+54.45% YoY). Revenue growth accelerated in 3Q26, with a substantial improvement in profit. We believe the company's business growth has returned to a healthy trajectory, with notable results from cost reduction and efficiency improvement. Maintain BUY.
Self-produced reagent volume growth accelerated
In 9M26, self-produced product revenue was RMB1,238mn (+15.26% YoY), including self-produced reagent revenue of RMB884mn (+17.81% YoY). In 3Q26, both self-produced reagent revenue and self-produced CLIA reagent revenue grew 26% YoY, indicating accelerating growth in 3Q26. By region, domestic self-produced main business revenue was RMB1,009mn (+16.53% YoY) in 9M26, while overseas self-produced key business revenue was RMB229mn (+9.95% YoY). By product, autoimmune reagent revenue, the company's flagship product, grew 16.55% YoY in 9M26 and 18.42% YoY in 3Q26, further consolidating its domestic leadership position. Cardiovascular CLIA reagent revenue grew 56.80% YoY in 9M26 and 70.36% YoY in 3Q26, with the second growth curve accelerating into shape.
Self-produced CLIA instrument installations accelerated
In 9M26, the company installed 1,787 new self-produced CLIA instruments, including 1,197 units domestically (+24.3% YoY) and 590 units overseas. In 9M26, it installed 89 new assembly lines. As of end-9M26, cumulative installations of self-produced CLIA instruments amounted to 14,594 units, cumulative assembly line installations reached 390 units, and the coverage rate of domestic Grade-A Class-3 hospitals reached 70%.
GPM up, expense ratio down, with notably improved cash flow
In 9M26, the sales/administrative/R&D/financial expense ratios were 24.12/8.70/14.77/1.59% (+0.93/-1.34/-1.27/+0.53pp YoY), totaling 49.19% (-1.15pp YoY), reflecting effective expense control. In 9M26, the main business gross margin was 63.25% (+2.41pp YoY), with 3Q26 at 64.78% (+5.17pp YoY, +2.44pp QoQ). We attribute this to the company's continued lean improvement and cost reduction initiatives, as well as in-house raw material development replacing external procurement, driving costs down. In 9M26, the attributable net margin was 10.05% (+5.35pp YoY), with 3Q26 at 13.58% (+2.93pp QoQ), improving QoQ for three consecutive quarters. In 9M26, net operating cash flow was RMB381mn (+486.60% YoY), with a notable improvement in the alignment between operating quality and profit.
Earnings forecasts and valuation
We forecast 2026/2027/2028 attributable NP of RMB206/263/306mn, +783.9/ +27.4/+16.3% YoY, with EPS of RMB0.36/0.46/0.54. Considering the rapid development of the company's self-production business and the recovery in revenue growth after the domestic VBP impact diminishes, we value the stock at 30x 2027E PE (peers’ average of 20x on Wind consensus), with a target price of RMB13.80.
Risks: slower-than-we-expected volume ramp-up of CLIA instrument installations and specialty tests, and slower-than-we-expected overseas expansion.